Lupin receives tentative FDA approval for Rivaroxaban Tablets USP, ET HealthWorld

[ad_1]

Mumbai: Lupin Limited announced that it has received tentative approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg, to market a generic equivalent of Xarelto Tablets, 2.5 mg, 10 mg, 15 mg, and 20 mg, of Janssen Pharmaceuticals, Inc. This product will be manufactured at Lupin’s Pithampur facility in India.

Rivaroxaban Tablets USP are indicated to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, treatment of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), reduction in the risk of recurrence of DVT or PE, prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery, prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients, reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD), reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularisation due to symptomatic PAD, treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years, and thromboprophylaxis in paediatric patients two years and older with congenital heart disease after the Fontan procedure.

Rivaroxaban Tablets USP (RLD Xarelto) had estimated annual sales of $8,249 million in the US (IQVIA MAT November 2023).

  • Published On Jan 24, 2024 at 06:01 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


[ad_2]

Leave a Reply

Your email address will not be published. Required fields are marked *